Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (MIRM) has a dated narrative snapshot, but its priced-in model claim is temporarily suppressed because the model-solve record is unavailable or has changed.
296 institutional managers reported holding MIRM in 13F filings for the quarter ended 2026-03-31. 60 opened new positions that quarter. Held by Janus Henderson, Vanguard Group, BlackRock, among others. On the short side, 6.9M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (11.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
MIRM's share count grew 94.4% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at MIRM over the trailing three years: 2023: 6 buys totaling $4.60M; 2024: 4 buys totaling $115k; 2025: 10 buys totaling $280k; 2026: 1 buy totaling $9.00M. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
MIRM's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | +6.1% | +20.1% |
| 2023-11-03 | +5.6% | -3.8% |
| 2024-03-16 | -3.0% | -10.1% |
| 2024-05-09 | -0.3% | +45.8% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
MIRM's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-06-18 (items 5.07); 2026-05-18 (items 1.01, 2.03, 3.02, 8.01, 9.01); 2026-05-06 (items 2.02, 9.01); 2026-05-04 (items 8.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 8, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.